Tuesday, September 25, 2018 10:48:57 AM
There are some points that drove the price down yesterday:
1. expectations were way too high. Easy game for the shorts.
2. misunderstanding of ORR (prior data was unconfirmed RR, data from yesterday was confirmed), you can't compare unconfirmed (1 scan) to confirmed (2 scans)
3. The AE rate is very very high. The low discontinuation rate could be meaningless and just because MD Anderson is treating patients very well. I expect a much higher disc. rate in the two SPPI trials, another reason is that they upped the dose after dose reduction from 16/12/8 (MD Anderson) to 16/14/12 (SPPI trials).
4. there is better competition in HER2 exon20 as we saw on the conference. poziotinib isn't best in class there.
Nevertheless, chances of BTD in EGFR exon 20 IMHO are 75%. Worth speculating.
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM